Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Market Analysis & Valuation

UpdatedSep 09, 2025
DataAggregated Company Financials
Companies207
  • 7D1.0%
  • 3M-1.0%
  • 1Y2.8%
  • YTD5.3%

Over the last 7 days, the market has risen 1.0%, driven by gains of 1.7% in the Healthcare sector. As for last year, the market performance has been flat. As for the next few years, earnings are expected to grow by 11% per annum.

Trending IndustriesBiotech

Market Valuation and Performance

Has the Swiss Market valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 09 Sep 2025CHF 1.9tCHF 773.0bCHF 89.9b19.8x20.8x2.4x
Thu, 07 Aug 2025CHF 1.8tCHF 775.0bCHF 89.8b20.6x20.1x2.3x
Sat, 05 Jul 2025CHF 1.8tCHF 784.4bCHF 106.7b20.2x16.9x2.3x
Mon, 02 Jun 2025CHF 1.8tCHF 785.7bCHF 106.4b20.1x17.2x2.3x
Wed, 30 Apr 2025CHF 1.8tCHF 837.1bCHF 157.9b19.1x11.2x2.1x
Fri, 28 Mar 2025CHF 1.9tCHF 849.9bCHF 158.9b20x11.8x2.2x
Sun, 23 Feb 2025CHF 1.9tCHF 812.1bCHF 117.2b21.1x16.3x2.4x
Tue, 21 Jan 2025CHF 1.8tCHF 818.1bCHF 117.8b21.4x15.3x2.2x
Thu, 19 Dec 2024CHF 1.7tCHF 813.3bCHF 117.3b20.7x14.8x2.1x
Sat, 16 Nov 2024CHF 1.7tCHF 816.4bCHF 117.7b19.8x14.7x2.1x
Mon, 14 Oct 2024CHF 1.8tCHF 800.3bCHF 114.9b21.5x15.8x2.3x
Wed, 11 Sep 2024CHF 1.8tCHF 801.3bCHF 113.8b20.9x15.7x2.2x
Fri, 09 Aug 2024CHF 1.8tCHF 800.7bCHF 136.1b21.2x13x2.2x
Sun, 07 Jul 2024CHF 1.8tCHF 801.2bCHF 125.6b21.4x14.4x2.3x
Tue, 04 Jun 2024CHF 1.8tCHF 801.8bCHF 125.7b21.8x14.4x2.2x
Thu, 02 May 2024CHF 1.7tCHF 802.7bCHF 126.0b21.3x13.6x2.1x
Sat, 30 Mar 2024CHF 1.8tCHF 766.3bCHF 96.9b21.9x18.4x2.3x
Mon, 26 Feb 2024CHF 1.7tCHF 779.6bCHF 110.8b20.1x15.7x2.2x
Wed, 24 Jan 2024CHF 1.7tCHF 767.0bCHF 110.6b17.9x15.1x2.2x
Fri, 22 Dec 2023CHF 1.7tCHF 763.9bCHF 109.9b18.5x15.3x2.2x
Sun, 19 Nov 2023CHF 1.6tCHF 772.6bCHF 111.5b17.9x14.6x2.1x
Tue, 17 Oct 2023CHF 1.6tCHF 761.2bCHF 100.2b18.2x16.3x2.1x
Thu, 14 Sep 2023CHF 1.7tCHF 750.8bCHF 99.3b18.7x16.7x2.2x
Sat, 12 Aug 2023CHF 1.7tCHF 743.1bCHF 75.0b18.2x22.3x2.2x
Mon, 10 Jul 2023CHF 1.7tCHF 755.7bCHF 76.7b18.9x21.8x2.2x
Wed, 07 Jun 2023CHF 1.8tCHF 788.0bCHF 82.7b18.8x21.2x2.2x
Fri, 05 May 2023CHF 1.8tCHF 783.4bCHF 80.6b19.2x21.9x2.2x
Sun, 02 Apr 2023CHF 1.7tCHF 780.6bCHF 69.4b19.5x25x2.2x
Tue, 28 Feb 2023CHF 1.7tCHF 783.0bCHF 71.4b19.2x24.3x2.2x
Thu, 26 Jan 2023CHF 1.8tCHF 786.1bCHF 93.9b17.7x19x2.3x
Sat, 24 Dec 2022CHF 1.7tCHF 789.2bCHF 94.3b17.5x17.8x2.1x
Mon, 21 Nov 2022CHF 1.7tCHF 792.5bCHF 95.5b17.6x17.9x2.2x
Wed, 19 Oct 2022CHF 1.6tCHF 800.6bCHF 103.5b17x15.9x2.1x
Fri, 16 Sep 2022CHF 1.7tCHF 789.5bCHF 102.0b17.9x16.4x2.1x
Price to Earnings Ratio

16.4x


Total Market Cap: CHF 1.7tTotal Earnings: CHF 102.0bTotal Revenue: CHF 789.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Market Price to Earnings3Y Average 17.3x202320242025
Current Market PE
  • Investors are optimistic on the Swiss market, and appear confident in strong long term growth rates.
  • The market is trading at a PE ratio of 20.8x which is higher than its 3-year average PE of 17.3x.
Past Earnings Growth
  • The earnings for Swiss listed companies have declined 4.1% per year over the last three years.
  • Meanwhile revenues have been flat.
  • This means that either the cost of doing business or the level of investment back into businesses is increasing since sales have remained steady while profits have fallen.

Sector Trends

Which sectors have driven the changes within the Swiss Market?

CH Market1.03%
Consumer Discretionary3.25%
Industrials2.43%
Materials2.28%
Healthcare1.67%
Real Estate0.92%
Telecom0.31%
Consumer Staples-0.32%
Utilities-0.52%
Financials-0.84%
Tech-1.58%
Sector PE
  • Investors favour the Tech sector the most for future growth which is trading above its 3-year average PE ratio.
    • The market's confidence is likely because analysts are expecting annual earnings growth of 26.1% which is higher than its past year's earnings decline of 1.3% per year.
  • The Financials sector is the least preferred by investors for future growth. Although, investor sentiment seems to have improved given that it's trading above its 3-year average of 9.9x.
Forecasted Growth
  • Analysts are most optimistic on the Tech sector, expecting annual earnings growth of 26% over the next 5 years.
  • This is better than its past earnings decline of 1.3% per year.
  • In contrast, the Real Estate sector is expected to see its earnings decline by 6.6% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuationSector
ROG Roche HoldingCHF 270.103.8%
+CHF 8.4b		1.1%PE24.4xHealthcare
ABBN ABBCHF 55.944.1%
+CHF 4.0b		21.4%PE30.6xIndustrials
CFR Compagnie Financière RichemontCHF 143.953.7%
+CHF 3.0b		20.2%PE24.1xConsumer Discretionary
NOVN NovartisCHF 102.320.8%
+CHF 1.5b		2.7%PE18.3xHealthcare
AMRZ AmrizeCHF 43.525.7%
+CHF 1.3b		n/aPE25.6xMaterials
See more

Market Insights

Header cover image
💸 How to Navigate Lofty Valuations in 2025
Richard Bowman avatar
Richard Bowman
|
|
Why today’s lofty prices test investors, and how to stay invested without losing your edge.
Continue reading
🌊 The 2025 IPO Wave: Winners, Losers, and What Investors Should Watch
Last Week

🌊 The 2025 IPO Wave: Winners, Losers, and What Investors Should Watch

Latest News

LISN
CHF 124,400.00
Chocoladefabriken Lindt & Sprüngli
7D
3.5%
1Y
13.5%

Here's Why Chocoladefabriken Lindt & Sprüngli (VTX:LISN) Can Manage Its Debt Responsibly

Sep 09
Here's Why Chocoladefabriken Lindt & Sprüngli (VTX:LISN) Can Manage Its Debt Responsibly
TEMN
CHF 61.45
Temenos
7D
-13.9%
1Y
3.9%
ROG
CHF 270.10
Roche Holding
7D
3.8%
1Y
1.1%
ADEN
CHF 22.90
Adecco Group
7D
-10.5%
1Y
-16.5%

AI, Flexible Staffing And Upskilling Will Redefine Global Workforce

Adecco Group’s lower Future P/E ratio, indicating reduced earnings growth expectations, contrasts with an unchanged discount rate, resulting in the consensus price target staying flat at CHF26.24. What's in the News Adecco Group expects improved profitability in the second half of 2025 compared to the first half, signaling anticipated progress during H2.
NESN
CHF 74.72
Nestlé
7D
-1.0%
1Y
-15.2%

China And Digital Transformation Will Spur Consumer Demand

Analysts have modestly reduced price targets for Nestlé, citing undervaluation but ongoing concerns over brand strategy, restrictive dividends, and persistent underperformance, leaving the consensus fair value unchanged at CHF86.23. Analyst Commentary Valuation has become more attractive with Nestlé trading below 16x forward earnings and nearing decade-low levels.
PGHN
CHF 1,066.00
Partners Group Holding
7D
-2.8%
1Y
-3.9%

Regulatory Moves And Digital Solutions Will Expand Private Markets

Analyst price target revisions for Partners Group Holding reflect steady operational performance and favorable FX dynamics, offset by concerns around demanding consensus estimates and premium valuation, resulting in an unchanged fair value of CHF1238. Analyst Commentary Bullish analysts cited better than expected exit activity in recent weeks as a driver for price target increases.
ABBN
CHF 55.94
ABB
7D
4.1%
1Y
21.4%

Electrification And Automation Will Unlock Resilient Future Opportunities

Analysts have modestly raised ABB's price target to CHF51.11 amid improved earnings visibility and operational efficiency, but maintain a tempered outlook due to valuation sensitivity and sector headwinds. Analyst Commentary Bullish analysts are raising price targets due to improved earnings visibility and operational efficiency supporting incremental value.
SLHN
CHF 831.40
Swiss Life Holding
7D
-2.9%
1Y
19.1%
BEAN
CHF 823.50
BELIMO Holding
7D
-4.8%
1Y
44.2%

Is BELIMO Holding (VTX:BEAN) Using Too Much Debt?

Sep 01
Is BELIMO Holding (VTX:BEAN) Using Too Much Debt?
GALD
CHF 144.00
Galderma Group
7D
2.9%
1Y
80.0%

Global Aesthetics And Aging Trends Will Drive Expansion

Analysts have raised Galderma Group's price target to CHF140.69, reflecting strengthened conviction in early Nemluvio traction, robust pipeline execution, and sustained market share gains across dermatology. Analyst Commentary Bullish analysts cite strong early commercial traction and blockbuster potential for Nemluvio following its recent launch.
SDZ
CHF 48.02
Sandoz Group
7D
-4.3%
1Y
34.2%

Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities

Key Takeaways Accelerated biosimilar launches, improved manufacturing, and strong market share are driving margin expansion and long-term profitability. Strategic focus on international growth and a robust product pipeline positions the company for sustainable earnings momentum.
SGSN
CHF 86.46
SGS
7D
6.8%
1Y
-8.8%

Does SGS (VTX:SGSN) Have A Healthy Balance Sheet?

Aug 15
Does SGS (VTX:SGSN) Have A Healthy Balance Sheet?
AMRZ
CHF 43.52
Amrize
7D
5.7%
1Y
n/a
NOVN
CHF 102.32
Novartis
7D
0.8%
1Y
2.7%
ZURN
CHF 573.20
Zurich Insurance Group
7D
-0.8%
1Y
14.7%
CFR
CHF 143.95
Compagnie Financière Richemont
7D
3.7%
1Y
20.2%